查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1836884

血漿蛋白治療市場（按產品、適應症、給藥途徑和最終用戶分類）—全球預測 2025-2032

Plasma Protein Therapeutics Market by Product, Indication, Route Of Administration, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年血漿蛋白治療市場將成長至 878.1 億美元，複合年成長率為 11.71%。

主要市場統計數據
基準年2024年 361.9億美元
預計2025年 404.9億美元
預測年份：2032年 878.1億美元
複合年成長率（%） 11.71%

血漿蛋白療法的全面基礎介紹，解釋其生物學基礎、生產複雜性、臨床作用和策略系統層級依賴性

血漿蛋白療法是現代醫學的基石，涵蓋止血、免疫學和重症加護領域的救生應用。本導論概述了血漿衍生蛋白和重組蛋白的生物學原理，描述了核心生產途徑（包括供體採集和分離），並闡述了治療層級在現代臨床實踐中的地位。導論重點介紹了這些治療方法如何應對急性創傷、先天性出血性疾病、免疫力缺乏和標靶預防等疾病，並強調了其供應和交付背後的臨床緊迫性和操作複雜性。

引言部分概述了塑造該領域的系統性依賴因素，包括捐贈者的可用性、低溫運輸物流以及嚴格的病原體安全通訊協定。此外，引言還重點介紹了重組藥物製造和純化的進展，以及不斷發展的患者保護指南，闡明了技術創新與監管之間的相互作用。臨床醫生要求可預測的供應和一致的臨床表現，製造商必須在產能和品管之間取得平衡，而醫療保健系統則需要有彈性的採購途徑。這些綜合因素為以下章節中對技術變革、貿易動態和細分層面影響的更深入分析提供了背景。

對技術、監管和供應鏈變革性變化的深刻綜合，影響了血漿蛋白療法的生產、分銷和臨床應用

一系列融合且具有變革意義的變革正在再形成血漿蛋白療法的格局，這些變革正在改變血漿蛋白的生產、分銷和臨床應用。製造技術的進步加速了製程最佳化，實現了更高的產量、更佳的病毒惰性以及更具可擴展性的分離方法。同時，重組技術和替代表達平台日趨成熟，在傳統血漿衍生產品和生物工程替代品之間形成了新的競爭。

疫情期間的混亂和不斷升級的地緣政治貿易緊張局勢，使供應鏈的韌性成為重中之重。相關人員目前優先考慮多元化籌資策略、區域能力投資以及數位追溯，以確保持續性。在臨床方面，門診治療方法提高了患者的便利性，並推動了製劑調整和給藥方式的創新。法律規範也在同步發展，更加重視藥物安全檢測、批次可追溯性和安全標準的跨境協調。總而言之，這些變化需要一項涵蓋研發、製造、分銷和相關人員參與的整合策略，將科學進步轉化為有保障的患者可及性和永續的商業模式。

深入分析美國關稅變化如何改變整個血漿治療生態系統的供應鏈經濟、籌資策略和營運回應

美國近期實施的關稅政策變化，為全球血漿療法供應鏈的多個環節帶來了層層複雜性。對進口原料、專用耗材和某些生技藥品徵收的關稅，不僅增加了到岸成本，改變了供應商的選擇標準，也促使製造商重新評估籌資策略和合約條款。這些成本壓力將對來自關稅上調市場的上游投入產生尤為顯著的影響，促使企業考慮近岸外包、戰略性庫存建設或重新談判長期供應商契約，以保護利潤率並保持供應的連續性。

為應對這項挑戰，一些製造商正在加快對國內血漿分離能力的投資，並擴大與區域血漿採集網路的合作，以降低跨境關稅波動帶來的風險。付款人和採購團隊也在重新評估競標框架和報銷途徑，以反映調整後的採購成本。同時，監理合規和海關管控日益複雜，需要加強文件編制、提升關稅分類專業知識，並進行營運調整以避免延誤。最終，這種累積效應將推動全球血漿流動的再平衡，更加重視供應鏈透明度，並在成本、速度和冗餘之間進行務實的權衡，以保障患者用藥，同時保持商業性可行性。

深入的、細分主導的觀點，詳細介紹定義供需動態的產品類別、治療適應症、給藥途徑和護理環境

細分分析揭示了產品類別、適應症、給藥途徑和最終用戶的細微趨勢，這些趨勢影響著臨床實踐和商業策略。按產品類型，白蛋白對於容量管理和重症加護仍然至關重要，低濃度和高濃度配方適用於各種臨床情況。凝血因子，包括具有不同半衰期和給藥複雜性的因子，繼續導致遺傳性和後天性出血性疾病，而凝血酶原複合物濃縮物可快速矯正。針對病原體的高免疫球蛋白製劑為肝炎、狂犬病、破傷風和帶狀皰疹等疾病提供有針對性的預防和暴露後選擇，並在集體爆發應對中保持臨床相關性。免疫球蛋白治療在免疫調節中起著核心作用，可透過靜脈或皮下給藥，途徑的選擇會影響患者體驗、輸液設定和給藥頻率。

就適應症而言，心血管支持、神經免疫調節、原發性和次發性免疫力缺乏以及創傷相關免疫力缺乏各自驅動不同的需求模式和臨床路徑。給藥途徑影響醫療保健提供模式。機構環境中的傳統靜脈注射與日益普及的皮下給藥方式競爭，後者支持家庭給藥並降低醫院資源利用率。最後，診所和醫院等最終用戶表現出不同的採購行為和產能限制。醫院通常管理急性住院需求和複雜的倉儲物流，而診所擴大支持慢性病管理和分散護理。這些細分為最佳化可近性和依從性所需的產品開發優先順序、通路策略和臨床支援模型提供了資訊。

區域評估重點關注美洲、中東和非洲以及亞太地區的不同基礎設施、監管環境和舉措

在全球血漿蛋白治療領域，區域動態持續影響產能、可及性和監管導向。美洲地區受益於成熟的捐贈網路、一體化的分餾基礎設施以及支持批量收集和配送的物流系統。雖然該地區的產能支撐著可靠的供應，但也面臨著成本上漲和監管審查的壓力，需要持續投資於品質。

複雜的監管體系和差異化的報銷框架決定了歐洲、中東和非洲地區產品供應和應用的節奏。在某些市場，先進的臨床路徑和強大的醫院系統推動著複雜療法的可及性；而在其他市場，有針對性的可及性項目和能力建設對於擴大利用率至關重要。該地區的政策制定者越來越重視協調可追溯性和安全性，這會影響跨境供應和合規成本。

亞太地區正經歷需求快速成長、本地製造投資不斷擴大以及血漿採集能力波動的動態組合。醫療保健可近性的提高、臨床醫生對血漿療法認知度的提升以及對區域血漿分離能力的策略性投資，正在推動血漿產能擴張。然而，不同市場的供應彈性各不相同，這要求製造商調整分銷模式、投資本地夥伴關係關係，並製定教育計劃，以使臨床實踐與一流的安全性和有效性標準保持一致。

清楚概述企業策略，重點在於產能投資、技術差異化、合作夥伴關係和塑造競爭定位的綜合服務模式

領先企業和區域性企業之間的競爭動態反映了策略重點，包括產能擴張、產品差異化和垂直整合。老牌製造商持續投資於先進的分餾設施、病原體減少技術，並不斷擴展分銷網路，以保持供應可靠性和合規性。同時，新興的生物技術和合約開發公司正在開發重組生產平台和特殊製劑，旨在滿足尚未滿足的臨床需求或提供劑量優勢。

策略夥伴關係、授權協議和定向收購已成為現有企業保障產品平臺、取得新技術和擴大地理覆蓋範圍的常用途徑。品質系統、批次一致性和可追溯性是幫助醫院和診所做出採購決策的競爭優勢。此外，企業正在擴展患者支援服務，對臨床醫生進行路線選擇和家庭治療通訊協定的培訓，並與付款人合作，使臨床表現與報銷一致。總而言之，這些發展描繪出一個強調整合解決方案、可預測供應和可證明臨床效益作為核心商業要素的市場圖景。

領導者提出了一系列切實可行、影響深遠的建議，以增強供應彈性、擴大獲取管道並加速整個血漿治療價值鏈的創新

產業領導者應採取積極主動的議程，解決供應彈性、臨床可及性和長期創新問題。首先，透過區域夥伴關係實現採購多元化，並擴大血漿採集網路，可以減輕貿易緊張和關稅導致的成本波動的影響。投資模組化、可擴展的生產能力以及先進的病毒去活化和純化技術，可以提高營運靈活性並增強品質保證。

第二，優先考慮支持門診和家庭用藥的產品和交付創新，特別是透過擴大皮下製劑配方和患者培訓舉措。這種轉變將減輕醫院負擔，提高依從性，同時開闢新的銷售管道。第三，儘早與監管機構和付款人進行建設性接觸，以協調證據產生和報銷預期，並簡化跨境合規途徑。第四，實施強而有力的供應鏈透明度措施和情境規劃，以因應中斷，包括策略性庫存佈局和降低風險的合約條款。最後，透過在整個價值鏈中部署數位工具並最佳化捐贈者招募、低溫運輸監控和藥物安全檢測，提高可追溯性和營運效率。這些綜合行動將在短期韌性與長期競爭力和以患者為中心的成果之間取得平衡。

一種透明的混合方法研究途徑，結合主要相關人員訪談、次要技術檢驗和情境分析，以支持可行的策略見解

本執行摘要所依據的研究採用了混合方法，旨在捕捉營運現狀和策略觀點。主要的定性研究包括與臨床專家、生產主管、採購負責人和監管專業人員進行結構化訪談，以突出該領域的挑戰和新興實踐。這些見解與二手文獻、行業技術指南和公開的監管文件相結合，以檢驗趨勢並識別技術曲折點。

分析過程採用主題綜合法處理質性數據，運用營運圖譜評估供應鏈，並運用情境分析探討貿易政策變化的影響。研究者仔細考慮了資料來源和來源的三角測量，以減少偏差並增強對定向研究結果的信心。研究的限制包括監管變化的速度不一以及專有製造指標的保密性限制。儘管如此，該調查方法仍強調透明度、可重複性和相關性，以便決策者能夠根據臨床、營運和監管現狀尋求可操作的資訊。

綜合技術、供應和政策促進因素得出明確結論，闡明維持血漿蛋白療法獲取途徑和競爭的策略重點

總而言之，雖然血漿蛋白療法對現代醫療保健仍然至關重要，但該領域正在經歷重大變革時期。生產和製劑技術的進步、支持以患者為中心的給藥模式的不斷發展，以及對供應鏈韌性的日益重視，正在共同重新定義製造商和醫療保健系統的運作方式。不斷變化的貿易政策和不斷發展的法規使營運環境進一步複雜化，促使我們採取策略性應對措施，優先考慮本地能力、透明度以及與付款人和監管機構的合作。

展望未來，整合對生產穩健性、創新劑型和有針對性的臨床證據生成的投資的組織將最有能力在保持商業性可行性的同時，確保可靠的患者可及性。預測市場波動、調整採購和分銷策略以及協調圍繞品質和可追溯性的跨職能舉措的能力，將決定誰能在這種複雜的環境中取得成功。因此，相關人員應將這一關鍵時刻視為一個機遇，以現代化營運模式、加強整個價值鏈的夥伴關係，並在日益以患者為中心的環境中提供可衡量的臨床效益。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 重組血漿蛋白製造技術的進步減少了對捐贈者血漿供應的依賴
  • 原發性免疫力缺乏患者擴大採用皮下免疫球蛋白治療
  • 引進新型病毒去活化技術，增強血漿製品安全性
  • 診斷篩檢的改進推動了對 α-1 抗胰蛋白酶增強療法的需求
  • 生物製藥公司與血漿採集中心的策略合作擴大了高免疫球蛋白產品組合
  • 下一代凝血因子獲得監管部門核准，改善血友病治療方案
  • 用於單株免疫球蛋白生產的細胞表現平台的出現降低了成本
  • 供應鏈數位化和低溫運輸最佳化確保免疫球蛋白的持續供應

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 血漿蛋白治療市場（依產品）

  • 白蛋白
    • 5%
    • 25%
  • 凝血因子
    • 凝血因子IX
    • 第八因子
    • 凝血酶原複合物濃縮物
  • 高免疫球蛋白
    • B型肝炎
    • 狂犬病
    • 破傷風
    • 水痘帶狀皰疹
  • 免疫球蛋白
    • 靜脈注射免疫球蛋白
    • 皮下注射免疫球蛋白

9. 血漿蛋白治療市場（按適應症）

  • 心血管系統
  • 神經系統
  • 原發性免疫力缺乏缺陷症
  • 次發性免疫力缺乏
  • 創傷

10. 依給藥途徑分類的血漿蛋白治療市場

  • 肌肉注射
  • 靜脈
  • 口服
  • 皮下

第 11 章。血漿蛋白治療市場（按最終用戶）

  • 診所
  • 醫院

12. 血漿蛋白治療市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章血漿蛋白治療市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 血漿蛋白治療市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • CSL Behring LLC
    • Takeda Pharmaceutical Company Limited
    • Grifols, SA
    • Octapharma AG
    • Biotest AG
    • Baxter International Inc.
    • Kedrion SpA
    • LFB SA
    • Pfizer Inc.
    • ADMA Biologics
Product Code: MRR-030EE4851670

The Plasma Protein Therapeutics Market is projected to grow by USD 87.81 billion at a CAGR of 11.71% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 36.19 billion
Estimated Year [2025] USD 40.49 billion
Forecast Year [2032] USD 87.81 billion
CAGR (%) 11.71%

A comprehensive foundational introduction that explains the biological basis, production complexity, clinical roles, and strategic system-level dependencies of plasma protein therapeutics

Plasma protein therapeutics constitute a cornerstone of modern clinical care, spanning life-saving applications in hemostasis, immunology, and critical care. This introduction frames the biological rationale for plasma-derived and recombinant proteins, explains core production pathways such as donor collection and fractionation, and situates therapeutic classes within contemporary clinical practice. It highlights how these therapies address acute trauma, congenital bleeding disorders, immune deficiencies, and targeted prophylaxis, emphasizing both the clinical urgency and the operational complexity that underpin supply and delivery.

Moreover, the introduction outlines systemic dependencies that shape the sector, including donor availability, cold-chain logistics, and rigorous pathogen safety protocols. It presents the interplay between innovation and regulation, noting advances in recombinant production and purification alongside evolving guidance to safeguard patients. Finally, it clarifies the strategic stakes for stakeholders: clinicians require predictable supply and consistent clinical performance, manufacturers must balance capacity and quality controls, and health systems need resilient procurement pathways. Together, these elements create the context for deeper analysis of technological shifts, trade dynamics, and segmentation-level implications provided in the subsequent sections.

An insightful synthesis of transformative technological, regulatory, and supply chain shifts reshaping production, distribution, and clinical adoption of plasma protein therapies

The landscape for plasma protein therapeutics has been reshaped by a set of convergent, transformative shifts that alter production, distribution, and clinical use. Advances in manufacturing technologies have accelerated process optimization, enabling higher yields, improved viral inactivation, and more scalable fractionation approaches. At the same time, recombinant techniques and alternative expression platforms are maturing, creating new competitive dynamics between traditional plasma-derived products and biologically engineered alternatives.

Supply chain resilience has moved to the forefront, driven by pandemic-era disruptions and heightened geopolitical trade friction. Stakeholders now prioritize diversified sourcing strategies, regional capacity investments, and digital traceability to ensure continuity. Clinically, there is a clear pivot toward therapies that enable outpatient administration and improved patient convenience, prompting formulation adaptations and delivery innovations. Regulatory frameworks are evolving in parallel, with greater emphasis on pharmacovigilance, batch traceability, and cross-border harmonization of safety standards. Taken together, these shifts demand integrated strategies across R&D, manufacturing, distribution, and stakeholder engagement to translate scientific advances into reliable patient access and sustainable commercial models.

A detailed analysis of how evolving United States tariff measures are altering supply chain economics, sourcing strategies, and operational responses across the plasma therapeutics ecosystem

Recent tariff policy changes implemented by the United States have introduced a layer of complexity that affects multiple nodes of the global plasma therapeutics supply chain. Tariffs on imported raw materials, specialized consumables, and certain finished biologics increase landed costs and alter supplier selection criteria, prompting manufacturers to re-evaluate sourcing strategies and contractual terms. These cost pressures are disproportionately felt where upstream inputs originate from markets subject to elevated duties, leading firms to consider nearshoring, strategic inventory buildup, or renegotiation of long-term supplier agreements to protect margins and maintain supply continuity.

In response, some manufacturers are accelerating investments in domestic fractionation capacity and expanding partnerships with regional plasma collection networks to reduce exposure to cross-border tariff volatility. Payers and procurement teams are also reassessing tender frameworks and reimbursement pathways to reflect adjusted acquisition costs. Meanwhile, regulatory compliance and customs administration become more complex, requiring enhanced documentation, tariff classification expertise, and operational adjustments to avoid delays. Ultimately, the cumulative effect incentivizes a rebalancing of global flows, greater emphasis on supply chain transparency, and pragmatic trade-offs between cost, speed, and redundancy to protect patient access while preserving commercial viability.

A thorough segmentation-driven perspective detailing product classes, therapeutic indications, administration routes, and care settings that define demand and delivery dynamics

Segmentation analysis reveals nuanced trends across product classes, indications, routes of administration, and end users that shape clinical practice and commercial strategy. Within product categories, albumin remains critical for volume management and critical care, with formulations spanning lower and higher concentration presentations suited to different clinical scenarios. Coagulation factors continue to serve hereditary and acquired bleeding disorders, including products for factors that vary in half-life and administration complexity, while prothrombin complex concentrates offer rapid correction capabilities. Hyperimmune globulins tailored to specific pathogens provide targeted prophylaxis and post-exposure options for diseases such as hepatitis, rabies, tetanus, and varicella zoster, and they retain clinical relevance in outbreak responses. Immunoglobulin therapies maintain a central role in immune modulation, delivered either intravenously or via subcutaneous routes, with route choice influencing patient experience, infusion setting, and dosing cadence.

Regarding indications, cardiovascular support, neurological immune modulation, primary and secondary immunodeficiencies, and trauma-related resuscitation each drive distinct demand patterns and clinical pathways. Routes of administration influence healthcare delivery models: traditional intravenous delivery in institutional settings competes with growing adoption of subcutaneous alternatives that enable home administration and reduce hospital resource utilization. Finally, end users such as clinics and hospitals demonstrate different procurement behaviors and capacity constraints; hospitals typically manage acute inpatient demand and complex storage logistics, whereas clinics increasingly support chronic therapy administration and decentralized care. Together, these segmentation layers inform product development priorities, channel strategies, and clinical support models needed to optimize access and adherence.

A nuanced regional assessment highlighting the differing infrastructure, regulatory landscapes, and capacity initiatives across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics continue to influence capacity, access, and regulatory navigation across the global continuum of plasma protein therapeutics. The Americas landscape benefits from a well-established donor network, integrated fractionation infrastructure, and logistical systems that support high-volume collection and distribution. This regional capability underpins supply reliability but also faces pressure from cost inflation and regulatory scrutiny that demand continuous quality investments.

In Europe, Middle East & Africa, regulatory complexity and heterogeneous reimbursement frameworks shape product availability and adoption rhythms. Some markets feature advanced clinical pathways and robust hospital systems that drive complex therapy utilization, while others require targeted access programs and capacity building to expand availability. Policymakers in the region are increasingly focused on traceability and safety harmonization, which affects cross-border supply and compliance costs.

Asia-Pacific presents a dynamic mix of rapid demand growth, expanding local manufacturing investments, and variable plasma collection capacity. Increasing healthcare access, rising clinician awareness of plasma therapies, and strategic investments in regional fractionation capabilities are fostering capacity expansion. However, supply resilience remains uneven across markets, requiring manufacturers to tailor distribution models, invest in local partnerships, and deploy education programs to align clinical practice with best-in-class safety and efficacy standards.

An incisive overview of company strategies emphasizing capacity investment, technological differentiation, alliances, and integrated service models that shape competitive positioning

Competitive dynamics among leading firms and regional players reflect strategic priorities that include capacity expansion, product differentiation, and vertical integration. Established manufacturers continue to invest in state-of-the-art fractionation facilities, pathogen reduction technologies, and extended distribution networks to maintain supply reliability and regulatory compliance. At the same time, emerging biotechnology companies and contract developers are advancing recombinant production platforms and specialty formulations intended to address unmet clinical needs or offer administration advantages.

Strategic partnerships, licensing agreements, and targeted acquisitions have become common pathways for incumbents to secure product pipelines, access novel technologies, or strengthen regional footprints. Quality systems, lot-to-lot consistency, and traceability are competitive differentiators that inform procurement decisions by hospitals and clinics. Additionally, companies are expanding patient support services, educating clinicians on route selection and home-based therapy protocols, and collaborating with payers to align reimbursement with clinical outcomes. These combined moves illustrate a marketplace that values integrated solutions, predictable supply, and demonstrable clinical benefit as core commercial imperatives.

A set of pragmatic, high-impact recommendations for leaders to strengthen supply resilience, broaden access, and accelerate innovation across the plasma therapeutics value chain

Industry leaders should adopt a proactive agenda that addresses supply resilience, clinical accessibility, and long-term innovation. First, diversifying sourcing through regional partnerships and expanding plasma collection networks can reduce exposure to trade friction and tariff-driven cost volatility. Investing in modular and scalable manufacturing capacity, as well as advanced viral inactivation and purification technologies, will improve operational flexibility and strengthen quality assurance.

Second, prioritize product and delivery innovations that support outpatient and home-based administration, particularly by expanding subcutaneous formulations and patient training initiatives. These shifts reduce hospital burden and enhance adherence while opening new commercial channels. Third, engage early and constructively with regulators and payers to align evidence generation with reimbursement expectations and to streamline cross-border compliance pathways. Fourth, implement robust supply chain transparency measures and scenario planning to manage disruptions, including strategic inventory positioning and contractual clauses that mitigate risk. Finally, embed digital tools across the value chain to optimize donor recruitment, cold-chain monitoring, and pharmacovigilance, thereby enhancing traceability and operational efficiency. Together, these actions will balance short-term resilience with long-term competitiveness and patient-centered outcomes.

A transparent mixed-methods research approach combining primary stakeholder interviews, secondary technical validation, and scenario analysis to support actionable strategic insights

The research underpinning this executive summary employed a mixed-methods approach designed to capture both operational realities and strategic perspectives. Primary qualitative engagement included structured interviews with clinical specialists, manufacturing leaders, procurement officers, and regulatory experts to surface frontline challenges and emergent practices. These insights were triangulated with secondary literature, industry technical guidance, and publicly available regulatory documents to validate trends and identify technological inflection points.

Analytical processes applied thematic synthesis for qualitative data, operational mapping for supply chain assessment, and scenario analysis to explore the implications of trade policy shifts. Careful attention was given to data provenance and source triangulation to limit bias and increase confidence in directional findings. Limitations include the variable speed of regulatory changes and the confidentiality constraints around proprietary manufacturing metrics, both of which can limit granularity. Nevertheless, the methodology emphasizes transparency, reproducibility, and relevance for decision-makers seeking actionable intelligence grounded in clinical, operational, and regulatory realities.

A decisive conclusion synthesizing technological, supply, and policy drivers to clarify strategic priorities for sustaining access and competitiveness in plasma protein therapies

In conclusion, plasma protein therapeutics remain indispensable to modern healthcare, yet the sector is navigating a period of significant transformation. Technological advances in production and formulation, evolving administration paradigms that favor patient-centric delivery, and heightened attention to supply chain resilience collectively redefine how manufacturers and health systems must operate. Trade policy shifts and regulatory evolution further complicate the operating environment, prompting strategic responses that prioritize regional capacity, transparency, and collaborative engagement with payers and regulators.

Moving forward, organizations that integrate investments in manufacturing robustness, innovative delivery formats, and targeted clinical evidence generation will be best positioned to sustain reliable patient access while preserving commercial viability. The ability to anticipate disruptions, adapt procurement and distribution strategies, and align cross-functional initiatives around quality and traceability will determine who succeeds in this complex landscape. Stakeholders should therefore view this juncture as an opportunity to modernize operational models, strengthen partnerships across the value chain, and deliver measurable clinical benefit in an increasingly patient-centric environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advances in recombinant plasma protein manufacturing reducing reliance on donor plasma supply
  • 5.2. Increasing adoption of subcutaneous immunoglobulin therapies for primary immunodeficiency patients
  • 5.3. Implementation of novel viral inactivation techniques enhancing safety of fractionated plasma products
  • 5.4. Rising demand for alpha-1 antitrypsin augmentation therapy driven by better diagnostic screening
  • 5.5. Strategic collaborations between biopharma and plasma collection centers to expand hyperimmune globulin portfolios
  • 5.6. Regulatory approvals for next-generation coagulation factors improving treatment options for hemophilia
  • 5.7. Emergence of cell-based expression platforms for monoclonal immunoglobulin production reducing costs
  • 5.8. Supply chain digitalization and cold chain optimization ensuring uninterrupted immunoglobulin availability

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Plasma Protein Therapeutics Market, by Product

  • 8.1. Albumin
    • 8.1.1. Five Percent
    • 8.1.2. Twenty Five Percent
  • 8.2. Coagulation Factor
    • 8.2.1. Factor IX
    • 8.2.2. Factor VIII
    • 8.2.3. Prothrombin Complex Concentrate
  • 8.3. Hyperimmune Globulin
    • 8.3.1. Hepatitis B
    • 8.3.2. Rabies
    • 8.3.3. Tetanus
    • 8.3.4. Varicella Zoster
  • 8.4. Immunoglobulin
    • 8.4.1. Intravenous Immunoglobulin
    • 8.4.2. Subcutaneous Immunoglobulin

9. Plasma Protein Therapeutics Market, by Indication

  • 9.1. Cardiovascular
  • 9.2. Neurological
  • 9.3. Primary Immunodeficiency
  • 9.4. Secondary Immunodeficiency
  • 9.5. Trauma

10. Plasma Protein Therapeutics Market, by Route Of Administration

  • 10.1. Intramuscular
  • 10.2. Intravenous
  • 10.3. Oral
  • 10.4. Subcutaneous

11. Plasma Protein Therapeutics Market, by End User

  • 11.1. Clinics
  • 11.2. Hospitals

12. Plasma Protein Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Plasma Protein Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Plasma Protein Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. CSL Behring LLC
    • 15.3.2. Takeda Pharmaceutical Company Limited
    • 15.3.3. Grifols, S.A.
    • 15.3.4. Octapharma AG
    • 15.3.5. Biotest AG
    • 15.3.6. Baxter International Inc.
    • 15.3.7. Kedrion S.p.A.
    • 15.3.8. LFB S.A.
    • 15.3.9. Pfizer Inc.
    • 15.3.10. ADMA Biologics

LIST OF FIGURES

  • FIGURE 1. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. PLASMA PROTEIN THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. PLASMA PROTEIN THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PLASMA PROTEIN THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FIVE PERCENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FIVE PERCENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FIVE PERCENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FIVE PERCENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FIVE PERCENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FIVE PERCENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TWENTY FIVE PERCENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TWENTY FIVE PERCENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TWENTY FIVE PERCENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TWENTY FIVE PERCENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TWENTY FIVE PERCENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TWENTY FIVE PERCENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FACTOR IX, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FACTOR IX, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FACTOR IX, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FACTOR IX, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FACTOR IX, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FACTOR IX, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FACTOR VIII, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FACTOR VIII, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FACTOR VIII, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FACTOR VIII, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FACTOR VIII, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY FACTOR VIII, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HEPATITIS B, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HEPATITIS B, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY RABIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY RABIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY RABIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY RABIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY RABIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY RABIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TETANUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TETANUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TETANUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TETANUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TETANUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TETANUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY VARICELLA ZOSTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY VARICELLA ZOSTER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY VARICELLA ZOSTER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY VARICELLA ZOSTER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY VARICELLA ZOSTER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY VARICELLA ZOSTER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TRAUMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TRAUMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TRAUMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TRAUMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TRAUMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY TRAUMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY ALBUMIN, 2025-2032 (USD MILLION)
  • TABLE 293. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2018-2024 (USD MILLION)
  • TABLE 294. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY COAGULATION FACTOR, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY HYPERIMMUNE GLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 297. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 298. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 299. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 300. AFRICA PLASMA PROTEIN THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 301. AFRICA PLASMA PROTEIN THERAPEUT